Franklin Resources Inc. lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 1.4% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,896,086 shares of the biopharmaceutical company’s stock after selling 27,016 shares during the quarter. Franklin Resources Inc. owned approximately 1.73% of Regeneron Pharmaceuticals worth $1,912,695,000 as of its most recent filing with the SEC.
Other large investors have also modified their holdings of the company. Rakuten Securities Inc. raised its stake in Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 19 shares in the last quarter. Stephens Consulting LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at approximately $26,000. Sachetta LLC lifted its stake in Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 10 shares during the last quarter. FSA Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals in the third quarter worth $26,000. Finally, Family Firm Inc. bought a new stake in Regeneron Pharmaceuticals during the second quarter valued at $33,000. Institutional investors own 83.31% of the company’s stock.
Regeneron Pharmaceuticals Stock Performance
REGN opened at $740.97 on Friday. The business has a 50 day moving average price of $855.40 and a two-hundred day moving average price of $1,005.56. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The company has a market capitalization of $81.43 billion, a price-to-earnings ratio of 18.34, a price-to-earnings-growth ratio of 2.32 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a 1-year low of $735.95 and a 1-year high of $1,211.20.
Wall Street Analysts Forecast Growth
View Our Latest Stock Report on Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Recommended Stories
- Five stocks we like better than Regeneron Pharmaceuticals
- When to Sell a Stock for Profit or Loss
- Top 3 Robotics and Automation Stocks for the Next AI Boom
- 10 Best Airline Stocks to Buy
- Why a Stock Split Could Be a Game-Changer for Casey’s in 2025
- How Technical Indicators Can Help You Find Oversold StocksĀ
- Where to Invest in 2025: Top Stock Picks for Maximum Gains
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.